Restoration of thrombopoietin production after partial splenic embolization leads to resolution of thrombocytopenia in liver cirrhosis

Hepatology Research

Volumn 23, Issue 4, 2002, Pages 265-273

  Hidaka, Hisashi ^a   Kokubu, Shigehiro ^a   Saigenji, Katsunori ^a   Isobe, Yoshinori ^b   Maeda, Tadanobu ^b  

^a KITASATO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b KITASATO UNIVERSITY HOSPITAL   (Japan)

Author keywords

Megakaryocyte; Platelets; PSE; TPO

Indexed keywords

ALANINE AMINOTRANSFERASE; BILIRUBIN; THROMBOPOIETIN;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ARTIFICIAL EMBOLISM; CONTROLLED STUDY; FEMALE; HUMAN; HYPOCHONDRIASIS; LIVER CIRRHOSIS; LIVER FUNCTION; MALE; MEGAKARYOCYTE; PORTAL HYPERTENSION; PRIORITY JOURNAL; PROTHROMBIN TIME; SPLEEN; THROMBOCYTE COUNT; THROMBOCYTOPENIA; THROMBOCYTOPOIESIS;

EID: 0038195640     PISSN: 13866346     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1386-6346(02)00002-5     Document Type: Article

References (41)

1. Aster RH. Pooling of platelets in the spleen: role in the pathogenesis of 'hypersplenic' thrombocytopenia. J Clin Invest 1964;45:645-57.
2. Kutti J, Weinfeld A, Westin J. The relationship between splenic platelet pool and spleen size. Scand J Haematol 1972;9:351-4.
3. 75Se-selenomethionine in patients with hepatic cirrhosis and thrombocytopenia. Thromb Haemost 1977;37:47-52.
4. Watanabe Y. The mechanism of the thrombocytopenia in patients with hepatic cirrhosis. [English abstract]. Jpn J Gastroenterol 1981;78:1216-25.
5. Aoki Y, Hirai K, Tanikawa K. Mechanism of thrombocytopenia in liver cirrhosis: kinetics of indium-111 tropolone labeled platelets. Eur J Nucl Med 1993;20:123-9.
6. Kawasaki T, Takesita A, Souda K, et al. Serum thrombopoietin levels in patients with chronic hepatitis and liver cirrhosis. Am J Gastroenterol 1999;94:1918-22.
7. Kato T, Ogami K, Shimada Y, et al. Purification and characterization of thrombopoietin. J Biochem 1995;118:229-36.
8. De Sauyage FJ, Hass PE, Spencer SD, et al. Stimulation of megakaryocytopoiesis and thrombopoiesis by the c-Mp1 ligand. Nature 1994;369:533-8.
9. Hartley TD, Pogenberger J, Hunt P, et al. Identification and cloning of a megakaryocyte growth and development factor that is a ligand for the cytokine receptor Mp1. Cell 1994;77:1117-24.
10. Wendling F, Maraskovsky E, Debili N, et al. c-Mp1 ligand is a humoral regulator of megakaryocytopoiesis. Nature 1994;369:571-4.
11. Kaushansky K. Thrombopoietin: the primary regulator of platelet production. Blood 1995;86:419-31.
12. Zeigler FC, de Sauvage F, Widmer R, et al. In vitro megakaryocytopoitic and thrombopoietic activity of c-Mp1 ligand (TPO) on purified murine hematopoitic stem cell. Blood 1994;84:4045-52.
13. Tahara T, Usaki K, Sato H, et al. A sensitive sandwich ELISA for measuring thrombopoietin in human serum: serum thrombopoietin levels in healthy volunteers and in patients with haemopoietic disorders. Br J Haematol 1996;93:783-8.
14. Peck-Radosavljevic M, Wichlas M, Pidrich J, et al. Blunted thrombopoietin response to interferon alfa-induced thrombocytopenia during treatment for hepatitis C. Hepatology 1998;28:1424-9.
15. Bernardi M, Palareti G, Pini P, et al. Study on coagulation profile of patients with cirrhosis of the liver undergoing elective fibreoptic injection sclerotherapy of oesophageal varices. Hepatogastroenterology 1984;31:125-8.
16. Maddison FE. Embolic therapy of hypersplenism. Invest Radiol 1973;8:280-1.
17. Noguchi H, Hirai K, Aoki Y, et al. Changes in platelet kinetics after a partial splenic arterial embolization in cirrhotic patients with hypersplenism. Hepatology 1995;22:1682-8.
18. Okuda K, Kono K, Ohnishi K, et al. Clinical study of eighty-six cases of idiopathic portal hypertension and comparison with cirrhosis with splenomegaly. Gastroenterology 1984;86:600-10.
19. Sangro B, Bilbao I, Herrero I, et al. Partial splenic embolization for the treatment of hypersplenism in cirrhosis. Hepatology 1993;18:309-14.
20. Terada H, Kono J, Nishimura K, et al. Megakeryogram, and the numbers of megakaryocytes and nucleated cells in bone marrow on various hematological disease with particular reference to the leukemia. [English abstract]. Jpn J Clin Hemarol 1968;9:13-21.
21. Matsutani S, Kimura K, Ohio M, et al. Ultrasonography in the diagnosis of portal hypertension. In: Okuda K, editor. Portal hypertension clinical and physiological aspects. Tokyo: Springer, 1991:197-206.
22. Sezai S, Kamisaka K, Ikeguchi F, et al. Regulation of hepatic thrombopoietin production by portal hemodynamics in liver cirrhosis. Am J Gastroenterol 1998;93:80-2.
23. Kato N, Yosida H, Ono-Nita S. Measurement of serum thrombopoietin (TPO) level in patients with liver disease. [English abstract]. Jpn Pharmacol Ther 1998;26:439-43.
24. Spigos DG, Jonasson O, Mozes M, et al. Partial splenic embolization in the treatment of hypersplenism. Am J Radiol 1979;132:777-82.
25. Germenis A, Antipas SE, Dimitiou P, Politis C, et al. Assessment of splenic and RES function of patients with thalassemia major long after partial splenic embolization. Eur J Hematol 1988;40:466-72.
26. Brandt CT, Rothbart LJ, Kumpe D, et al. Splenic embolization in children: long-term efficacy. J Pediatr Surg 1989;24:642-4.
27. Alwmark A, Bengmark S, Gullstrand P, et al. Evaluation of splenic embolization in patients with portal hypertension and hypersplenism. Ann Surg 1982;196:518-24.
28. Sakata K, Hirai K, Tanikawa K. A long-term investigation of transcatheter splenic arterial embolization for hypersplenism. Hepato-Gastroenterology 1996;43:309-18.
29. Murata K, Shiraki K, Takase K, et al. Long-term follow-up for patients with liver cirrhosis after partial splenic embolization. Hepato-Gastroenterology 1996;43:1212-7.
30. Numata S, Akagi K, Sakino I, et al. Partial splenic embolization for the treatment of liver cirrhosis with hypersplenism: assessment of clinical response and liver function. [English Abstract]. Jpn J Gastroenterol 1997;94:526-31.
31. McDonald TP. Thrombopoietin. Its biology clinical aspect, possibilities. Am J Pediatr Hematol Oncol 1992;14:8-21.
32. Goulis J, Chau TN, Jordan S, et al. Thrombopoietin concentrations are low in patients with cirrhosis and thrombocytopenia and are restored after orthotopic liver transplantation. Gut 1999;44:754-8.
33. Ohira M, Umeyama K, Taniura M, et al. An experimental study of a splenic inhibitory factor influencing hepatic regeneration. Surg Gynecol Obstet 1987;164:438-44.
34. Sato K, Tanaka M, Tanikawa K. The effect of spleen volumes on liver regeneration after hepatectomy-a clinical study of liver and spleen volumes by computed tomography. Hepato-Gastroenterology 1995;42:961-5.
35. Porter BA, Frey CF, Link DP, et al. Splenic embolization monitored by the video dilution technique. Am J Roentgenol 1985;141:1063-5.
36. Hirai K, Kawazoe Y, Yamashita K, et al. Transcatheter partial splenic arterial embolization in patients with hypersplenism: a clinical evaluation as supporting therapy for hepatocellular carcinoma and liver cirrhosis. Hepatogastroenterology 1986;33:105-8.
37. Ohmoto K, Iguchi Y, Miyake I, et al. Long-term evaluation of partial splenic embolization for liver cirrhosis and hepatocellular carcinoma accompanied by hypersplenism. Hepatol Res 1998;11:73-83.
38. Kuter DJ, Rosenberg RD. The reciprocal relationship of thrombopoietin (c-Mp1 ligand) to changes in the platelet mass during busulfan-induced thrombocytopenia in the rabbit. Blood 1995;85:2720-30.
39. Ishida A, Miyakawa Y, Tanosaki R, et al. Circulating endogenous thrombopoietin, interleukin-3, interleukin-6 and interleukin-11 levels in patients undergoing allogenic bone marrow transplantation. Int J Hematol 1996;65:61-9.
40. Vadhan-Raj S, Murray LJ, Bueso-Ramos C, et al. Stimulation of megakaryocyte and platelet production by a single dose of recombinant human thrombopoietin in patients with cancer. Ann Intern Med 1997;126:673-81.
41. Basser RL, Rasko JE, Clarke K, et al. Thrombopoietic effects of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) in patients with advanced cancer. Lancet 1996;348:1279-81.